Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
Revenues	$	226		$	96		$	581		$	271
Less:
Cost of revenues		18			10			43			31
Acquired in-process research and development expense		—			—			1,967			—
Depreciation and amortization expense		528			530			1,588			1,578
Stock-based compensation expense		70			17			259			36
Salaries and benefits expense		1,027			1,236			3,651			2,957
Professional fees		582			373			1,626			1,419
Research and development expense		276			63			534			181
Interest income		(10	)		(7	)		(31	)		(47	)
Interest expense		83			32			199			40
Change in fair value of royalties payable due to related parties		(726	)		1,233			2,104			2,823
Change in fair value of trading debt securities		(107	)		—			(117	)		—
Income tax benefit		78			—			(1,596	)		—
Other segment items (1)		751			729			2,201			2,268
Segment net loss		(2,344	)		(4,120	)		(11,847	)		(11,015	)
Reconciliation of net loss
Adjustments and reconciling items		—			—			—			—
Consolidated net loss	$	(2,344	)	$	(4,120	)	$	(11,847	)	$	(11,015	)

Fair Value, by Balance Sheet Grouping [Table Text Block]

			September 30, 2025
	Total		Level 1		Level 2		Level 3
Assets:
Cash Equivalents
Mutual funds	$	900	$	900	$	—	$	—
Money market funds		123		123		—		—
Trading debt securities		981		—		—		981
Total assets	$	2,004	$	1,023	$	—	$	981
Liabilities:
Current portion of royalties payable due to related parties	$	574	$	—	$	—	$	574
Royalties payable due to related parties		10,743		—		—		10,743
Total liabilities	$	11,317	$	—	$	—	$	11,317

			December 31, 2024
	Total		Level 1		Level 2		Level 3
Assets:
Cash Equivalents
Mutual funds	$	2,803	$	2,803	$	—	$	—
Money market funds		12		12		—		—
Total assets	$	2,815	$	2,815	$	—	$	—
Liabilities:
Current portion of royalties payable due to related parties	$	145	$	—	$	—	$	145
Royalties payable due to related parties		9,068		—		—		9,068
Total liabilities	$	9,213	$	—	$	—	$	9,213

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Royalties Payable due to Related Parties			Trading Debt Securities
Balance at January 1, 2025	$	9,213		$	—
Change in fair value		1,163			—
Balance at March 31, 2025		10,376			—
Purchased		—			864
Change in fair value		1,667			10
Balance at June 30, 2025		12,043			874
Change in fair value		(726	)		107
Balance at September 30, 2025	$	11,317		$	981

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Royalties Payable due to Related Parties		Trading Debt Securities
Balance at January 1, 2024	$	6,974	$	—
Change in fair value		86		—
Balance at March 31, 2024		7,060		—
Change in fair value		1,504		—
Balance at June 30, 2024		8,564		—
Change in fair value		1,233		—
Balance at September 30, 2024	$	9,797	$	—

Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]

Machinery and equipment	2 - 5 years
Computer hardware and software	1 - 5 years
LockeT animation video	3 years
VIVO DEMO/Clinical Systems	1-5 years

Disaggregation of Revenue [Table Text Block]

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2025		2024		2025		2024
Product sales
US	$	172	$	62	$	480	$	129
Europe		54		34		101		142
Total product sales	$	226	$	96	$	581	$	271

Royalties Payable [Member]

Notes Tables

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

September 30, 2025
Instrument	Valuation Technique	Unobservable Input	Input Range
Royalties payable due to related parties	Discounted future cash flows	Revenue adjusted discount rate		19.5	%
Trading debt securities	Probability weighted expected return	Recovery rate		60.0	%
		Simulated conversion price	$	0.67
		Credit risk-adjusted discount rate		11.5	%
		Expected equity volatility		90	%
		Probability of conversion		25.8	%
		Probability of payment		74.2	%
		Expected term for conversion (years)		1.8
		Expected term for payment (years)		5.0

December 31, 2024
Instrument	Valuation Technique	Unobservable Input	Input Range
Royalties payable due to related parties	Discounted future cash flows	Revenue adjusted discount rate		22.5	%